Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is on Fire Today

By George Budwell – Nov 1, 2021 at 9:35AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech announced three major regulatory updates for its COVID-19 vaccine this morning.

What happened

Shares of the next-generation vaccine developer Novavax (NVAX -1.17%) jumped by as much as 15% in premarket trading Monday morning. The company's stock is up by double-digits in early morning action today in response to three positive regulatory updates for its protein-based COVID-19 vaccine candidate known as NVX-CoV2373.

Specifically, ahead of the opening bell, the biotech announced that it has now completed the vaccine's regulatory application in Canada and submitted all of the necessary regulatory paperwork for the vaccine's approval in the European Union. Novavax noted in its press release that the final step to completing the application in the European Union will be an invitation from the European Medicines Agency to file for Conditional Marketing Authorization. Additionally, the biotech also announced that Indonesia has granted the vaccine emergency use authorization in the country, marking the vaccine's first official regulatory approval. 

A healthcare worker gives a patient an injection.

Image source: Getty Images.

So what

Novavax's shares have essentially been in free fall over the last few weeks. Investors have been backing away from this COVID-19 vaccine stock of late due to a combination of missed regulatory deadlines and concerns about the manufacturing process for its vaccine. In fact, Novavax's shares were down by a whopping 53% from their 52-week highs prior to this morning's sizable rally. The long and short of it is that Novavax is slowly but surely proving its critics wrong with this series of regulatory filings for NVX-CoV2373.   

Now what

Is Novavax's stock a buy on this news? I think the answer is a resounding yes. The biotech's shares were unfairly punished for an article in Politico that relied on anonymous sources to question the capabilities of its manufacturing partners. While Novavax has indeed missed its self-imposed regulatory deadlines for the all-important U.S. market this year, these global regulatory filings are proof positive that the company can manufacture this vaccine at scale. Novavax's stock, in turn, should continue to rebound for the remainder of the year. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.